CureVac Sues Moderna Over COVID-19 Vaccine Patent Claims

• CureVac alleges Moderna infringed eight U.S. patents by copying its mRNA stabilization technology for use in the Spikevax vaccine
• BioNTech, which partnered with Pfizer on competing vaccine Comirnaty, also sued Moderna in February over its next-generation mNEXSPIKE shot
• Multiple biotech companies are pursuing patent royalties from COVID-19 vaccine makers, with Moderna itself having sued Pfizer and BioNTech over Comirnaty in 2022

CureVac Sues Moderna Over COVID-19 Vaccine Patent Claims

Key Development:

German biotech company CureVac filed a patent infringement lawsuit against Moderna in Delaware federal court on April 24, alleging that Moderna's COVID-19 vaccine Spikevax violated CureVac's intellectual property rights related to messenger RNA (mRNA) technology.

Patent Claims:

CureVac accused Moderna of infringing eight U.S. patents, specifically alleging that Moderna copied its technology for stabilizing fragile mRNA used in vaccines. CureVac is seeking royalties from Spikevax sales as damages.

Companies Involved:

• CureVac: German biotech plaintiff
• Moderna: Defendant, manufacturer of Spikevax COVID-19 vaccine
• BioNTech/Pfizer: Previously sued Moderna in similar mRNA patent disputes last year and filed separate U.S. litigation in February over Moderna's next-generation mNEXSPIKE vaccine
• Moderna: Counter-sued BioNTech and Pfizer in 2022 over their Comirnaty vaccine in ongoing litigation

Market Context:

This lawsuit represents part of a broader wave of patent litigation in the biotech sector, with multiple companies seeking royalties from the highly profitable COVID-19 vaccine market. The legal battle highlights the valuable intellectual property underlying blockbuster mRNA vaccine technology.

Company Response:

Moderna acknowledged awareness of the lawsuit and stated it would defend itself. CureVac and BioNTech spokespeople did not immediately provide comments.

Implications:

The outcome could significantly impact royalty payments and future mRNA vaccine development, as multiple patent disputes continue to unfold among major biotech players who developed COVID-19 vaccines. The litigation underscores ongoing disputes over fundamental mRNA technologies that generated substantial revenues during the pandemic.